1. Home
  2. PHGE vs ROMA Comparison

PHGE vs ROMA Comparison

Compare PHGE & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHGE
  • ROMA
  • Stock Information
  • Founded
  • PHGE 2015
  • ROMA 2018
  • Country
  • PHGE Israel
  • ROMA Hong Kong
  • Employees
  • PHGE N/A
  • ROMA N/A
  • Industry
  • PHGE Biotechnology: Pharmaceutical Preparations
  • ROMA Savings Institutions
  • Sector
  • PHGE Health Care
  • ROMA Finance
  • Exchange
  • PHGE Nasdaq
  • ROMA Nasdaq
  • Market Cap
  • PHGE 13.3M
  • ROMA 18.1M
  • IPO Year
  • PHGE N/A
  • ROMA 2024
  • Fundamental
  • Price
  • PHGE $0.56
  • ROMA $2.02
  • Analyst Decision
  • PHGE Strong Buy
  • ROMA
  • Analyst Count
  • PHGE 2
  • ROMA 0
  • Target Price
  • PHGE $23.00
  • ROMA N/A
  • AVG Volume (30 Days)
  • PHGE 51.4K
  • ROMA 116.2K
  • Earning Date
  • PHGE 05-15-2025
  • ROMA 12-16-2024
  • Dividend Yield
  • PHGE N/A
  • ROMA N/A
  • EPS Growth
  • PHGE N/A
  • ROMA N/A
  • EPS
  • PHGE N/A
  • ROMA N/A
  • Revenue
  • PHGE N/A
  • ROMA $1,029,120.00
  • Revenue This Year
  • PHGE N/A
  • ROMA N/A
  • Revenue Next Year
  • PHGE N/A
  • ROMA N/A
  • P/E Ratio
  • PHGE N/A
  • ROMA N/A
  • Revenue Growth
  • PHGE N/A
  • ROMA N/A
  • 52 Week Low
  • PHGE $0.48
  • ROMA $0.40
  • 52 Week High
  • PHGE $4.99
  • ROMA $2.05
  • Technical
  • Relative Strength Index (RSI)
  • PHGE 44.80
  • ROMA 95.55
  • Support Level
  • PHGE $0.54
  • ROMA $1.04
  • Resistance Level
  • PHGE $0.58
  • ROMA $1.18
  • Average True Range (ATR)
  • PHGE 0.04
  • ROMA 0.19
  • MACD
  • PHGE 0.00
  • ROMA 0.09
  • Stochastic Oscillator
  • PHGE 32.83
  • ROMA 65.22

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage and overcome various business matters arising from such factors related to ESG, sustainability and climate change. it provides tailored-made sustainability solutions to meet the client's specific needs. Its mission is to provide its clients with a one-stop destination for high-quality and holistic sustainability and climate change-related consulting services to support a more sustainable, balanced and inclusive future for its clients' organizations and the world.

Share on Social Networks: